{"entity":{"id":"rejuv-tx-survival-after-transplant","kind":"technology","name":"Survival after transplant, and why the curve never quite rejoins the population","aka":["late mortality after HSCT","long-term survival after transplant","excess mortality after transplant"],"tldr":"If you are alive and free of disease two years after a donor transplant, around nine in ten are alive five years later and 85 per cent at ten years. The death rate among transplant survivors stays higher than in people of the same age who never had one, for many years. The two things that matter most are age and chronic graft-versus-host disease.","summary":"Two large registry studies, eleven years apart, give the same answer with different numbers.\n\nThe International Bone Marrow Transplant Registry analysed 6,691 patients who were free of their original disease two years after allogeneic bone marrow transplantation and compared their mortality with an age, sex and nationality-matched general population. Among those disease-free at two years, the probability of living five more years was 89 per cent (95 per cent CI 88 to 90). For patients transplanted for aplastic anaemia, the risk of death by the sixth year after transplant did not differ significantly from a normal population. For acute lymphoblastic leukaemia and chronic myeloid leukaemia, mortality remained significantly higher than normal throughout the study; for acute myeloid leukaemia it remained higher through the ninth year. Recurrent leukaemia was the chief cause of death.\n\nThe CIBMTR repeated the exercise in a larger and later cohort: 10,632 patients worldwide who were alive and disease-free two years after a myeloablative allogeneic transplant performed before 2004 for acute myeloid or lymphoblastic leukaemia, myelodysplastic syndrome, lymphoma or severe aplastic anaemia. Median follow-up was nine years and 3,788 patients had been observed for ten years or more. The probability of being alive ten years after transplant was 85 per cent. The chief risk factors for late death were older age and chronic graft-versus-host disease. For those transplanted for a malignancy, relapse was the commonest cause of death, and the greatest risk factor for late relapse was advanced disease at transplantation. The principal risk factors for non-relapse death were older age and GvHD. Compared with an age, sex and nationality-matched general population, late deaths remained higher than expected for each disease, with the possible exception of lymphoma.\n\nTwo honest qualifications belong next to those numbers. First, both cohorts are conditional on surviving two years disease-free, so they describe the outlook from that point and not from the day of transplant. Second, both describe transplants performed with the conditioning, supportive care and donor matching of their era; the CIBMTR cohort is of transplants before 2004. Supportive care, prophylaxis and donor selection have changed since, and the direction of change in non-relapse mortality has been downwards, so a person transplanted today is not described exactly by either curve.\n\nWhat does not change is the shape of the finding, and it is the frame for every other record in this file. Mortality after a successful transplant falls steeply and then flattens at a level above the background rate, and the gap is made of relapse, second cancers, infection, lung disease and chronic GvHD. Every one of those has a surveillance or prevention step attached to it. The curve is the argument for long-term follow-up, not a verdict about any individual.","status":"established","asOf":"2026-10-02","wikipedia":"https://en.wikipedia.org/wiki/Hematopoietic_stem_cell_transplantation","links":[{"label":"Socie et al., Long-term survival and late deaths after allogeneic bone marrow transplantation, Late Effects Working Committee of the IBMTR (NEJM 1999)","url":"https://doi.org/10.1056/NEJM199907013410103"},{"label":"Wingard et al., Long-term survival and late deaths after allogeneic hematopoietic cell transplantation (JCO 2011)","url":"https://doi.org/10.1200/JCO.2010.33.7212"},{"label":"Inamoto and Lee, Late effects of blood and marrow transplantation (Haematologica 2017)","url":"https://doi.org/10.3324/haematol.2016.150250"}],"tags":["rejuvenation","survivorship","transplant","late-effects","survival"],"related":["rejuv-tx-late-effects-overview","rejuv-tx-second-cancers","gvhd-chronic-overview","rejuv-tx-long-term-follow-up-frameworks"],"cancers":[],"sections":["rejuvenation","supportive-care"],"technologies":["allogeneic-hsct","survivorship-care-plan"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["late-effects","secondary-malignancy"],"trials":[],"people":[],"bottlenecks":["b-survivorship"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Late mortality after transplant is the sum of a declining hazard, relapse of the original disease, and a slowly rising hazard, the late effects of conditioning and of chronic alloimmunity. Because the second component rises with time while the first falls, total excess mortality flattens rather than reaching zero, and the longer a cohort is followed the more of the excess is non-relapse.","strengths":["Two large registry cohorts, 6,691 and 10,632 patients, with long follow-up","85 per cent alive at ten years among two-year survivors in the later cohort","Mortality for aplastic anaemia converged with the general population by the sixth year","Risk factors for late death are identified and two of them, GvHD control and relapse surveillance, are acted on"],"limitations":["Both analyses are conditional on being alive and disease-free at two years","The larger cohort describes transplants performed before 2004","Excess mortality persisted for every malignant diagnosis studied, with lymphoma the possible exception","Registry data cannot adjust for everything that differs between transplanted and general populations"]},"route":"/technologies/rejuv-tx-survival-after-transplant/","neighbours":{"technology":[{"id":"rejuv-tx-what-to-ask-for","kind":"technology","name":"After a transplant or cell therapy: what to ask for","route":"/technologies/rejuv-tx-what-to-ask-for/"},{"id":"allogeneic-hsct","kind":"technology","name":"Allogeneic stem cell transplantation","route":"/technologies/allogeneic-hsct/"},{"id":"gvhd-chronic-overview","kind":"technology","name":"Chronic graft-versus-host disease","route":"/technologies/gvhd-chronic-overview/"},{"id":"rejuv-tx-late-effects-overview","kind":"technology","name":"Late effects after a stem cell transplant","route":"/technologies/rejuv-tx-late-effects-overview/"},{"id":"rejuv-tx-second-cancers","kind":"technology","name":"Second cancers after allogeneic transplant","route":"/technologies/rejuv-tx-second-cancers/"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/"},{"id":"rejuv-tx-long-term-follow-up-frameworks","kind":"technology","name":"Who is supposed to be watching: EBMT, CIBMTR, FACT-JACIE, and what a survivor is actually offered","route":"/technologies/rejuv-tx-long-term-follow-up-frameworks/"}],"section":[{"id":"rejuvenation","kind":"section","name":"Recovery & Rejuvenation","route":"/fronts/rejuvenation/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"term":[{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/"},{"id":"secondary-malignancy","kind":"term","name":"Secondary malignancy (therapy-related cancer)","route":"/terms/secondary-malignancy/"}],"bottleneck":[{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/"}]}}